Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 21, 2026 14:50 ET | Source: ODDIFACT

ODDIFACT Receives European Commission Orphan Drug Designation for Infliximab in Kawasaki Disease

ODDIFACT obtient la désignation médicament orphelin de l'EMA pour l'infliximab dans la maladie de Kawasaki, après la FDA. Essai KIDCARE dans The Lancet.
May 21, 2026 14:50 ET | Source: ODDIFACT

ODDIFACT obtient la désignation médicament orphelin de la Commission Européenne pour l’infliximab dans la maladie de Kawasaki

ODDIFACT obtient la désignation médicament orphelin de l'EMA pour l'infliximab dans la maladie de Kawasaki, après la FDA. Essai KIDCARE dans The Lancet.
May 01, 2026 06:50 ET | Source: Research and Markets

Adalimumab, Infliximab and Etanercept Biosimilars Trastuzumab Biosimilars Research Report 2026: $8.05 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2035

Dublin, May 01, 2026 (GLOBE NEWSWIRE) -- The "Adalimumab, Infliximab and Etanercept Biosimilars Market Report 2026" has been added to ResearchAndMarkets.com's offering. The adalimumab,...
February 12, 2025 04:04 ET | Source: Research and Markets

$22.68 Bn Adalimumab, Infliximab, Etanercept and Trastuzumab Biosimilars Market Opportunities and Strategies to 2033

Dublin, Feb. 12, 2025 (GLOBE NEWSWIRE) -- The "Adalimumab, Infliximab, Etanercept and Trastuzumab Biosimilars Market Opportunities and Strategies to 2033" report has been added to ...
September 26, 2024 04:17 ET | Source: Research and Markets

U.S. Psoriasis Treatment Awareness & Satisfaction Report: A Review of 2023 - Provides Valuable Insights Into Must-Have Patient-Reported Data Points

Dublin, Sept. 26, 2024 (GLOBE NEWSWIRE) -- The "Psoriasis in the United States: A Review of 2023 - Key Insights into Treatment Awareness & Satisfaction" report has been added to ...
January 26, 2024 03:17 ET | Source: Research and Markets

Psoriasis Global Market Report 2024: Market to Surge to $39.17 Billion by 2028, Middle East Poised for Rapid Growth - Long-term Forecasts to 2033

Dublin, Jan. 26, 2024 (GLOBE NEWSWIRE) -- The "Psoriasis Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The psoriasis market is undergoing significant...
January 23, 2024 11:48 ET | Source: Research and Markets

Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Outlook 2024-2028: Product Innovations and Strategic Partnerships Catalyzing Industry Growth

Dublin, Jan. 23, 2024 (GLOBE NEWSWIRE) -- The "Tumor Necrosis Factor Inhibitor Drugs Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The tumor necrosis...
December 05, 2023 09:23 ET | Source: Emergen Research

Global Biosimilar Market Size to Reach USD 132.47 Billion in 2032 | Emergen Research

Vancouver, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Global Biosimilar Market Poised for Rapid Growth with 17.9% CAGR, Fueled by Rising Cancer Cases and Regulatory Approvals In 2032, the global biosimilar...
January 11, 2023 04:48 ET | Source: Research and Markets

Adalimumab, Infliximab And Etanercept Biosimilars Global Market Report 2023: Increasing Healthcare Access Bolsters Sector

Dublin, Jan. 11, 2023 (GLOBE NEWSWIRE) -- The "Adalimumab, Infliximab And Etanercept Biosimilars Global Market Opportunities And Strategies To 2031" report has been added to ...
August 10, 2022 05:28 ET | Source: Research and Markets

China Infliximab Market Investigation Report 2022: Sales 2017-2021, Major Manufacturers 2017-2021, Prices for Different Manufacturers 2021-2022 and Prospects 2022-2031

Dublin, Aug. 10, 2022 (GLOBE NEWSWIRE) -- The "Investigation Report on China's Infliximab Market 2022-2031" report has been added to ResearchAndMarkets.com's offering. According to this market...